As part of his latest research report on the biotech sector, Corporate Connect analyst Marc Sinatra gives some insights into what to consider when making an investment in this space.
Read More
Corporate Connect analyst Marc Sinatra has released a comprehensive research report on Antisense Therapeutics (ASX: ANP), placing a 12-month target on the company of $0.55 per share.
Read More
In a first time exclusive hear from Antisense Therapeutics (ASX: ANP) Managing Director & CEO – Mark Diamond, Chair – Charmaine Gittleson & Non-Executive Director – Gill Price.
Read MoreMorgans raises its target price to $0.58 from $0.45. The Speculative Buy rating is retained.
Read More
Mark Diamond – Managing Director and CEO – Antisense Therapeutics is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Read More
Corporate Connect analyst Marc Sinatra has released an update of his previous research report on Antisense Therapeutics, placing a 12-month price target on the company of $A0.48.
Read More
Managing Director and CEO Mark Diamond discusses the key highlights of the quarterly results for Antisense Therapeutics and other recent company news of note.
Read More
The US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read More
Charmaine Gittleson gives some insights into why she joined the ANP board, the way the FDA process works, and how this Type C meeting fits into clarifying the pathway to starting a clinical trial.
Read More
Presenter- Mark Diamond – CEO & MD -Antisense Therapeutics is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Read MoreThe Speculative Buy and $0.38 target price are maintained.
Read More
Australian biotechnology company Antisense Therapeutics Limited recently appointed Gil Price M.D. as a Consultant Medical Director. He spoke with with ShareCafe’s Tim McGowen about his new role.
Read More
Presenter – Mark Diamond, Managing Director & CEO – Antisense Therapeutics is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Read More
Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read MoreStockbroker Morgans has initiated coverage of Antisense Therapeutics with a Speculative Buy rating and a maiden price target of 37.7c.
Read More
Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.
Read More
Corporate Connect Research analyst Marc Sinatra recently published a research report on Antisense Therapeutics (ASX:ANP) with a 30.5 cent valuation. The report is available for free download.
Read More
Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read More
Our Hidden Gems series has provided insight into companies and industries with direct access to company CEOs. As a follow-up, we thought we would look back at our participating companies to determine the best-performing stocks post our webinars.
Read More
Antisense Therapeutics CEO Mark Diamond presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Antisense is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.
Read More
